

# ***Preliminary Program***

*(May 27, 2022)*

## **VACCINE TECHNOLOGY VIII**

**June 12 - 17, 2022**

**Sitges, Spain  
Melia Sitges Hotel**

### **Conference Co-Chairs**

**Francesc Godia**  
Universitat Autònoma de Barcelona, Spain

**Linda Hwee-Lin Lua**  
University of Queensland, Australia

**Charles Lutsch**  
Sanofi, France

**Tarit Mukhopadhyay**  
Merck Research Laboratories, USA



**Engineering Conferences International**  
32 Broadway, Suite 314 - New York, NY 10004, USA  
[www.engconfintl.org](http://www.engconfintl.org) – [info@engconfintl.org](mailto:info@engconfintl.org)

**Sunday, June 12, 2022**

- |               |  |
|---------------|--|
| 15:00 – 17:30 | Conference check-in  |
| 17:30 – 18:00 | Opening remarks  |
| 18:00 – 19:00 | <b><u>KEYNOTE</u></b><br><b>A tale of two worlds from the ongoing pandemic – unprecedented successes and all too familiar failures</b><br>David Robinson, The Bill & Melinda Gates Foundation, USA |
| 19:00 – 21:30 | Reception and Dinner   |

## **Monday, June 13, 2022**

07:00 – 08:30 Breakfast Buffet

### **Session 1: Technological and clinical advances in vaccinology**

Chairs: Florian Krammer, Icahn School of Medicine at Mount Sinai, USA  
Julià Blanco, IRSI Caixa, Spain

08:30 – 09:00

#### **Lead Speaker**

#### **Advances in therapeutic HIV vaccine development**

Christian Brander, IRSI Caixa, Spain

09:00 – 09:20

#### **SARS-CoV-2 and Ebola: CHO-based manufacturing provides high quality subunit-vaccine candidates and diagnostics**

Paco Pino, ExcellGene SA, Switzerland

09:20 – 09:40

#### **Microarray patch delivery of un-adjuvanted influenza vaccine induces potent and broad-spectrum immune responses in a phase I clinical trial**

Alexandra C. I. Depelseñaire, Vaxxas Pty Ltd, Australia

09:40 – 10:00

#### **Development of a thermostable, multivalent filovirus vaccine based on recombinant subunit proteins**

Axel T. Lehrer, University of Hawaii, USA

10:00 – 10:30

Coffee Break

### **Session 2: Technological and clinical advances in vaccinology**

Chairs: Sandy Douglas, University of Oxford, United Kingdom  
Barry Buckland, BioLogicB LLC, USA

10:30 – 11:00

#### **The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines**

Juan Manuel Carreño, Icahn School of Medicine at Mount Sinai, USA

11:00 – 11:20

#### **Targeting endogenous retroviruses using a novel adenoviral vaccine technology**

Anne-Marie Andersson, InProTher ApS, Denmark

11:20 – 11:40

#### **Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infection**

Sarah Thiroux, UGA, CNRS, CHU, France

11:40 – 12:00

#### **Superior SARS-CoV-2 RBD antigen designs for highly specific, quantitative serotests**

Miriam Klausberger, University of Natural Resources and Life Sciences, Austria

12:00 – 13:30

Lunch

13:30 – 14:30

### **KEYNOTE ON COVID-19 VACCINE**

#### **Learnings from the development of Covid-19 vaccines**

Kathrin Jansen, Pfizer, USA

## **Monday, June 13, 2022 (continued)**

14:30 – 16:00

**Workshop: Innovation in Global Health**

Workshop chairs: David Robinson, The Bill & Melinda Gates Foundation, USA  
Tarit Mukhopadhyay, Merck Research Laboratories, USA

16:00 – 17:00

Coffee Break / Networking

18:30 – 20:00

Dinner

20:00 – 22:00

**Poster session 1 (Odd numbers)**

Poster Chairs: Laura Cervera, UAB, Spain  
Antonio Roldao, IBET, Portugal

**Tuesday, June 14, 2022**

07:00 – 08:30 Breakfast Buffet

**Session 3: Next generation platforms**

Chairs: Amine Kamen, McGill University, Canada  
Fu Tong-Ming, IGM Biosciences, Inc., USA

08:30 – 09:00 **Lead Speaker**  
**Discovery & Development of Therapeutic Interfering Particles (TIPs): single-administration SARS-CoV-2 and HIV antivirals with high barriers to the evolution of resistance**  
Leor Weinberg, University of California, San Francisco, USA

09:00 – 09:15 **Towards a platform process for the manufacture of glycoconjugate vaccines for pneumococcal disease**  
Micheal Sulu, University College London, United Kingdom

09:15 – 09:30 **Enabling technologies for manufacturing thermostable and cost-effective vaccines**  
Justin Stanbro, Merck & Co., Inc., USA

09:30 – 09:45 **TBD**

09:45 – 10:00 **Genomics of Vero cells: Understanding this cell line and its virus-host interactions for improved vaccine production**  
Marie-Angelique Sene, McGill University, Canada

10:00 – 10:30 Coffee Break

10:30 – 12:00 **Workshop**  
**Crafting a Career in Bioscience**  
Workshop Chairs: Linda Lua, University of Queensland, Australia  
Manon Cox, Next Wave Bio, USA

12:00 – 13:30 Lunch

**Session 4 and 5: Bioprocessing advances in vaccine manufacturing**

Chairs: Martina Micheletti, University College London, United Kingdom  
Paula Alves, IBET, Portugal  
Tara Tagmyer, Merck & Co., Inc., USA

13:30 – 14:00 **Lead Speaker**  
**From genome to structure and beyond**  
Mariagrazia Pizza, GSK Vaccines, Italy

14:00 – 14:20 **Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting**  
Marc D. Hein, Max Planck Institute and Otto von Guericke University, Germany

14:20 – 14:40 **Development of an automated microscale platform for conjugate vaccine production in *E. coli***  
Jasmin J. Samaras, University College London, United Kingdom

**Tuesday, June 14, 2022 (continued)**

- 14:40 – 15:00      **Development of a purification process for HIV-1 VLPs based on four steps, from supernatant to lyophilization**  
Eliañet Lorenzo Romero, Universitat Autònoma de Barcelona, Spain
- 15:00 – 15:20      **AMBR®250 HT System: A key process development tool for new live virus and microbial vaccine candidates**  
Jessica Olson, Merck & Co, Inc., USA
- 15:20 – 15:40      **Enhancement of PCV viral antigen production: combined effect of feed based on metabolic requirements and mild hypothermia**  
Ziomara Gerdtzen, University of Chile, Chile
- 15:40 – 16:00      **Accelerating and intensifying manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 days**  
Sandy Douglas, University of Oxford, United Kingdom
- 16:00                Sitges activities  
Dinner on your own

**Wednesday, June 15, 2022**

07:00 – 08:30 Breakfast

**Session 6: Vaccine analytics I**

Chairs: Paula Lei, NIH/VRC, USA

Cristiana Kampa, GlaxoSmithKline, United Kingdom

08:30 – 09:00

**Lead Speaker**

**Driving change in dtap batch release testing**

Isabelle Bekeredjian-Ding, Paul-Ehrlich-Institute, Germany

09:00 – 09:20

**The implication of glycans on the ACE2: SARS-CoV-2 spike interaction**

Manuel Reithofer, University of Natural Resources and Life Sciences, Austria

09:20 – 09:40

**Generation of an international standard serum to measure influenza virus hemagglutinin stalk-reactive antibodies**

Juan Manuel Carreno Quiroz, Icahn School of Medicine at Mount Sinai, USA

09:40 – 10:00

**New insights in formaldehyde-induced detoxification of the tetanus toxin: Chemical modification stoichiometry and characterization of intra- and inter-molecular cross-links**

Thierry Eynard, Sanofi, France

10:00 – 10:30

Coffee Break

**Session 7: Vaccine analytics II**

Chairs: Laura Palomares, UNAM, Mexico

Patrice Riou, Sanofi, France

10:30 – 10:45

**Development of analytical characterization tools for process monitoring of adenovirus-based vaccines (ChAdOx and Ad5)**

Shaleem I. Jacob, University College London, United Kingdom

10:45 – 11:00

**Novel application of flow virometry to monitor live virus vaccines**

Geoffrey Ricci, Merck & Co, Inc., USA

11:00 – 11:15

**On-Line influenza virus quantification for viral production processes thanks to affinity-based surface plasmon resonance biosensor**

Emma Petiot, ICBMS-Gembas Laboratory, France

11:15 – 11:30

**All doses are not the same: Potential role of vaccine quality in vaccine adverse reactions**

Bruce Yu, University of Maryland, USA

11:30 – 12:00

Panel Discussion

12:00 – 13:30

Lunch

13:30 – 14:30

**KEYNOTE**

**Development of the Oxford AstaZeneca Covid Vaccine**

Sarah Gilbert, University of Oxford, UK

**Wednesday, June 15, 2022 (continued)**

- 14:30 – 16:00      **Workshop: Intensified Vaccine Manufacturing**  
Workshop Chairs: Udo Reichl, Max-Planck-Institut Magdeburg, Germany  
Charles Lutsch, Sanofi, France
- Intensified manufacturing of engineered exosomes and their potential in advanced vaccine design**  
Konstantin Konstantinov, Codiak BioSciences, Inc., USA
- An aseptic platform process for recombinant measles viruses**  
Viktoria Mayer, BOKU, Vienna, Austria
- How can process intensification solve bottlenecks in vaccine manufacturing?**  
Amélie Boulais, Sartorius Stedim FMT S.A.S., France
- Process intensification considerations for LMIC**  
Philippe Alexandre Gilbert, Bill & Melinda Gates Foundation, USA
- How does process intensification impact distributed manufacturing and access?**  
Tania Pereira, Univercells Technologies, Belgium
- Discussion
- 16:00 – 17:00      Coffee Break
- Session 8: One health**  
Chairs: Diego Fontana, Universidad Nacional Del Litoral, Argentina  
Jean-Christophe Audonnet, Former Animal Health - Vaccine Industry leader,  
France
- 17:00 – 17:30      **Developing a ‘One Health’ Nipah virus vaccine to protect animal and public health**  
Simon P. Graham, The Pirbright Institute, UK
- 17:30 – 17:50      **Design of mimotopes of a conserved epitope in dengue and Zika viruses for the obtention of broadly neutralizing antibodies**  
Esmeralda Cuevas-Juárez, Instituto de Biotecnología, Mexico
- 17:50 – 18:10      **Sustained delivery of therapeutic nanobody cargo at the mucosal surfaces by engineered *Limosilactobacillus reuteri***  
Sambuddha Ghosh, Abel BioSolutions, Pune, India
- 18:10 – 18:30      **Adenovirus-based vaccine platform for mucosal or parenteral immunization of chickens**  
Omar Famos, McGill University, Canada
- 18:30 – 20:00      Dinner
- 20:00 – 22:00      **Poster session 2 (Even numbers)**  
Poster Chairs: Laura Cervera, UAB, Spain  
Antonio Roldao, IBET, Portugal



**Thursday, June 16, 2022**

- 07:00 – 08:30 Breakfast
- Session 9: Formulation and delivery**  
Chairs: QinJian Zhao, Xiamen University, China  
Lakshmi Khandke, PATH Center for Vaccine Innovation and Access, USA
- 08:30 – 09:00 **Lead Speaker**  
**Challenges and opportunities to formulate and stabilize vaccine candidates targeted for use in LMICs**  
David Volkin, The University of Kansas, USA
- 09:00 – 09:20 **Development of an oral protein subunit COVID-19 vaccine to induce mucosal and systemic immune response**  
Elodie Burette, VaxForm, LLC, USA
- 09:20 – 09:40 **TBA**
- 09:40 – 10:00 **Development of sulfated lactosyl archaeol (SLA) archaeosomes as a vaccine adjuvant**  
Michael McCluskie, National Research Council Canada, Canada
- 10:00 – 10:30 Coffee Break
- 10:40 – 12:00 **Workshop: Next Gen Sequencing**  
Workshop chairs: Jean-Pol Cassart, GSK, United Kingdom  
Marc Eloit, Institut Pasteur, France
- 12:00 – 13:30 Lunch
- Session 10: Capacity building and intervention plan**  
Chairs: Martin Elsenhaver, WHO, Switzerland  
Matthew Downham, CEPI, United Kingdom
- 13:30 – 14:00 **Lead Speaker**  
**Disease X development and 100 days initiative**  
Nicolas Havelange, CEPI, United Kingdom
- 14:00 – 14:24 **Developing an end to end manufacturing platform for self-amplifying messenger RNA vaccines**  
Kunal Aggarwal, GSK, USA
- 14:24 – 14:48 **A rapid response vaccine manufacturing platform as a countermeasure to epidemic threats**  
Tania Pereira Chilima, Univercells Technologies S.A., Belgium
- 14:48 – 15:12 **Advancing vaccine development and manufacture in Africa**  
Patrick Tippoo, African Vaccine Manufacturing Initiative, South Africa
- 15:12 – 15:36 **Test tubes and turnaround times: An accelerated biosafety testing approach for new vaccines against emerging pathogens**  
Sarah Sheridan, Merck, United Kingdom

**Thursday, June 16, 2022 (continued)**

- |               |  |
|---------------|--|
| 15:36 – 16:00 | <b>Production of high-quality SARS-CoV-2 antigens for vaccine development and serological assays implementation</b><br>Bárbara Fernandes, IBET, Portugal                       |
| 16:00 – 16:30 | Coffee Break   |
| 16:30 – 17:30 | Poster short talks   |
| 17:30 – 18:30 | <b><u>KEYNOTE</u></b><br><b>Shifting the paradigm from global to national: innovative approaches for sustainable production of priority vaccines</b><br>Birgitte Giersing, WHO |
| 18:30 – 19:00 | Closing<br>Conference Chairs   |
| 19:00 – 22:00 | Banquet  |

**Friday, June 17, 2022**

- |               |                                    |
|---------------|------------------------------------|
| 07:00 – 10:00 | Breakfast, Checkout and Departures |
|---------------|------------------------------------|